Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.

By N. Duma, R. Santana-Davila, J. Molina. Mayo Clinic proceedings, 2019

1,918 citations recorded by the source corpus.

Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non-small cell lung cancer (NSCLC). Screening has been introduced with the goal of early detection. The National Lung Screening Trial found a lung cancer mortality benefit of 20% and a 6.7% decrease in all-cause mortality with the use of low-dose chest computed tomography in high-risk individuals. The treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations. Similarly, immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of NSCLC treatment. Furthermore, the results of new trials continue to help us understand the role of these novel agents and which patients are more likely to benefit; ICIs are now part of the first-line NSCLC treatment armamentarium as monotherapy, combined with chemotherapy, or after definite chemoradiotherapy in patients with stage III unresectable NSCLC. Expression of programmed cell death protein-ligand 1 in malignant cells has been studied as a potential biomarker for response to ICIs. However, important drawbacks exist that limit its discriminatory potential. Identification of accurate predictive biomarkers beyond programmed cell death protein-ligand 1 expression remains essential to select the most appropriate candidates for ICI therapy. Many questions remain unanswered regarding the proper sequence and combinations of these new agents; however, the field is moving rapidly, and the overall direction is optimistic.

View Paper: https://www.semanticscholar.org/paper/60420387a1fe958eaf0fea478a66fa3c4eff5ebd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Zongang Liu
Yitong Xu
Jun Jiang
Qiongzi Wang
X. Qiu
Hongjiu Ren
Yao Zhang
Bo Zhang

Citations in the corpus

JMJD8 Promotes Malignant Progression of Lung Cancer by Maintaining EGFR Stability and EGFR/PI3K/AKT Pathway Activation (2021, background): “The current treatment of lung cancer mainly includes surgery, radiotherapy, and chemotherapy, but the long-term survival of lung cancer is still unsatisfactory, and the five-year survival rate has been maintained at 15% [4].”